ZIOP News and Press, ZIOPHARM Oncology Inc From 11/08/21

HOUSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced financial results for the third quarter ended September 30, 2021 and provided a business update. “I am impressed by the q...

ZIOPHARM Oncology (NASDAQ:ZIOP) is scheduled to announce Q3 earnings results on Monday, November 8th, after market close. The consensus EPS Estimate is -$0.13 (-30.0% Y/Y). Ziopharm cut 60 positions -- more than half of its headcount -- as part of a cost reduction effort to extend its ca...

HOUSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced that it will report financial results for the third quarter ended September 30, 2021 on Monday, November 8, 2021, after the close of U...

Are penny stocks with high short interest something that you’re looking for? This trend has become increasingly popular this year, thanks to retail traders. What began as a “fight against the hedgies” has rapidly evolved into something all its own. Massive breakouts fro...

Marine Petroleum Trust (NASDAQ:MARPS) +52%. U.S. Energy USEG +23% new assets to nearly quadruple production Annovis Bio (NYSE:ANVS) +16% announces positive phase 2 efficacy data for the treatment of parkinson's disease Team TISI +14% wins upstream mechanical insp...

On a day when macro concerns drove most of the trading on Wall Street, a hodge-podge of headlines triggered major single-stock moves in Tuesday's midday trading. This included an advance in shares of talent agency and media company Endeavor (NYSE:EDR), which sparked investor interest with a $...

Altimmune (NASDAQ:ALT) -19% after posts 12-week data from Phase 1 trial for weight loss therapy ZIOPHARM Oncology (NASDAQ:ZIOP) -15% after cuts half its workforce to extend cash runway. Paltalk (NASDAQ:PALT) -14%. Red Cat Holdings (OTCQB:RCAT) -11%. Entravision Communicati...

• Over 50% reduction in personnel • Cost reductions expected to extend the cash runway into the first half of 2023 • The first patient in its TCR-T Library Phase I/II clinical trial is expected to be dosed in 1H2022 BOSTON and HOUSTON, Sept. 27, ...

Shares of Ziopharm Oncology (NASDAQ: ZIOP) , jumped more than 30% on Tuesday. Shares of the clinical-stage biopharmaceutical company finished Thursday up around 18% from their closing price last Friday. While the company's been quiet, investors were highly encouraged by a handful of...

Gainers: ZIOPHARM Oncology (NASDAQ:ZIOP) +39%, RenovoRx (NASDAQ:RNXT) +17%, Sigilon Therapeutics (NASDAQ:SGTX) +17%, Acumen Pharmaceuticals (NASDAQ:ABOS) +15%, NeuroOne Medical Technologies (NASDAQ:NMTC) +7%. Losers: CorMedix (NASDAQ:CRMD) -25...